2 patents
Utility
Antibody-drug Conjugate Comprising Antibody Against Human ROR1 and Use for the Same
21 Dec 23
The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer.
Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
Filed: 13 Jun 23
Utility
Bispecific Antibody Against ALPHA-SYN/IGF1R and Use Thereof
9 Nov 23
The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
Sungwon AN, Jinhyung AHN, Byungje SUNG, Dongin KIM, Daehae SONG, Jaehyun EOM, Yong-Gyu SON, Juhee KIM, Kyungjin PARK, Jinwon JUNG, Bora LEE, Hyesu YUN
Filed: 8 Dec 22
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first